

# STANDARDIZED ONE PAGE PHARMACY PRIOR AUTHORIZATION FORM

**Mississippi Division of Medicaid,** Pharmacy Prior Authorization Unit, PO Box 2480, Ridgeland, MS 39158

☐ Medicaid Fee for Service/Gainwell Technologies
Fax to: 1-866-644-6147 Ph: 1-833-660-2402
https://medicaid.ms.gov/providers/pharmacy/pharmacy-prior-authorization/

Magnolia Health/Envolve Pharmacy Solutions
Fax to: 1-877-386-4695 Ph: 1-866-399-0928
nttps://www.magnoliahealthplan.com/providers/pharmacy.html
☐ <b>UnitedHealthcare</b> /OptumRx
Fax to: 1-866-940-7328 Ph: 1-800-310-6826
http://www.uhccommunityplan.com/health-professionals/ms/pharmacy-program.html
☐ <b>Molina Healthcare</b> /CVS Caremark
Fax to: 1-844-312-6371 Ph: 1-844-826-4335
http://www.molinahealthcare.com/providers/ms/medicaid/pages/home.aspx

BENEFICIARY INFORMATION				
Beneficiary ID: DOB:	//			
Beneficiary Full Name:				
PRESCRIBER INFORMATION				
Prescriber's NPI:				
Prescriber's Full Name:	Phone:			
Prescriber's Address:	FAX:			
PHARMACY INFORMATION				
Pharmacy NPI:				
Pharmacy Name:				
Pharmacy Phone:	Pharmacy FAX:			
CLINICAL INFORMATION				
Requested PA Start Date: Requested PA End Date:				
Drug/Product Requested: Strength: Quantity:				
Days Supply: RX Refills: Diagnosis or ICD-10 Code(s):				
Hospital Discharge Additional Medical Justification Attached				
Medications received through coupons and/or samples are not acceptable as justification				
PLEASE COMPLETE AND FAX DRUG SPECIFIC CRITERIA/ADDITIONAL DOCUMENTATION FORM FOUND BELOW				
Prescribing provider's signature (signature and date stamps, or the signature of anyone other than the provider, are not acceptable)				
I certify that all information provided is accurate and appropriately documented in the patient's medical chart.				
gnature required: Date:				
Printed name of prescribing provider:				

## **FAX THIS PAGE**

#### PRIOR AUTHORIZATION INFORMATION



### Brand-Name Multi-Source Drug / Dispense As Written (DAW)

The following brand name drugs are excluded from this requirement:

- DOM designated narrow therapeutic index drugs or NTI are Coumadin, Dilantin, Lanoxin, Synthroid, and Tegretol.
- Preferred branded drugs on DOM's PDL.

**The completed FDA MedWatch form must be included with this request.** A copy of the FDA MedWatch form may be obtained online at:

http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM163919.pdf

#### Medical Necessity Prior Authorization Form for EPSDT-eligible beneficiaries

The Division of Medicaid has established a program of Early and Periodic Screening., Diagnosis, and Treatment (EPSDT), which provides preventive and comprehensive health services for Medicaid-eligible children and youth up to the age twenty-one (21). The service ends on the last day of the beneficiary's twenty-first (21st) birthday month. See MS Administrative Code, Title 23, Part 223.

Reasons for prior authorization request may include, but are not limited to:
Request for more than 5 prescription claims per month
Request for more than 2 non-preferred/brand name prescription claims per month
Request for a non-preferred drug
Request for a non-covered drug

# CRITERIA/ADDITIONAL DOCUMENTATION BRAND NAME MULTI-SOURCE DRUG



BENEFICIARY INFORMATION					
Beneficiary ID:	DOB:	/	/		
Beneficiary Full Name:					
Brand Name Multi-Source Drug / Dispense As Written (DAW) Criteria					
MS Division of Medicaid requires that all information requested on this form be completed for consideration of approval					
<ul> <li>The following brand name drugs are excluded from this requirement:</li> <li>DOM designated narrow therapeutic index drugs or NTI are Coumadin, Dilantin, Lanoxin, Synthroid, and Tegretol.</li> <li>Preferred branded drugs on DOM's PDL.</li> </ul> The completed FDA MedWatch form must be included with this request. A copy of the FDA MedWatch form may be obtained online					
at: http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM163919.pdf  DOCUMENTATION OF TRIAL OF GENERIC PRODUCT					
DOCUMENTATION OF TRIAL OF GENERIC PRODUCT					
Generic Product: Manufacturer:	Length	of Therapy:			
Observed adverse reaction or allergic reaction:					
s					
Documentation Included: Yes No					
Generic Product: Manufacturer:	Length	of Therapy:			
Observed adverse reaction or allergic reaction:					
<u> </u>					
Documentation Included: Yes No					
Has a completed FDA MedWatch form been submitted to the FDA?	Yes No	•			
Printed Name of Prescribing Provider:	Date:		<del></del>		

**FAX THIS PAGE**